When the Medtech Carve-Out Becomes a Competitor

Two of medtech outsourcing’s largest companies changed ownership at the same time this past summer. While certainly newsworthy, the transactions should be a signal to all companies within the ecosystem of MPO’s Top 30 list.

On Aug. 3, two announcements landed within hours of each other. First, KKR acquired Integer Holdings in an all-cash transaction valued at $5.7 billion, taking one of the world’s largest contract development and manufacturing organizations private. Then that same day, Teleflex completed the $1.5 billion divestiture of its OEM business to Montagu and Kohlberg. The next morning, that 40-year-old business relaunched under a new name: INGENYX.

In the July/August column, we wrote about the Top 30 Companies’ “shrink to grow” reshaping and what it means for owners contemplating an exit. The supply base is now working through its own version of that story, and it deserves a separate conversation because the consequences land differently for OEM suppliers. For manufacturers that produce components, subassemblies, or finished devices for a partner’s label, their competitive set, customer concentration, and future buyer universe potentially all changed that day in early August. Such incidents have occurred before (i.e., Tyco’s spinoff of TE Connectivity, Vention’s division into MedPlast and Nordson, among others).

Two Deals, One Signal 

The numbers should be taken seriously. Integer stockholders will receive $127 per share, roughly a 51.8% premium to the closing price on April 29—the day before the company announced a strategic review, and about 28.8% above its 30-day volume-weighted average. That is what sophisticated capital is willing to pay for scaled, diversified outsourcing capability serving cardiovascular and neuromodulation end markets. The transaction is expected to close by year’s end. At MedWorld, while often not public information, we understand the value ranges and market dynamics for lower middle market OEM supplier companies because potential buyers regularly inquire about possible acquisition candidates in this segment.

INGENYX tells the complementary story. For more than four decades, the company operated as Teleflex Medical OEM, supplying custom-engineered interventional catheters and sub-assemblies, sutures, tubing, complex extrusions, and surgical fibers into structural heart, neurovascular, electrophysiology, and urology solutions from seven facilities across the United States, Ireland, and Mexico. Greg Stotts continues as CEO of the newly branded firm and Kohlberg senior operating partner Matt Jennings assumes the executive chairman seat. In theory, the business itself did not change but its ownership, its access to capital, and its mandate did—which has interesting impacts.

The common thread is straightforward. Capital that was previously rationed inside a diversified parent, or disciplined by quarterly public-market reporting, is now dedicated, patient, and explicitly pointed at growth within the medtech industry.

Three things change, and they change quickly, when an acquired entity becomes a platform.

The first to change is the mandate. As a division, an OEM business competes for capital against every other unit in the portfolio, and it usually loses to the higher-margin franchises. As a standalone platform, it is the investment thesis. Capital expenditure, capability build-out, and commercial coverage stop being an internal argument and become a board discussion/decision.

The second change is that conflict disappears. Acquired suppliers carry an inherent awkwardness in that many of their best prospects compete with the parent. Independence removes that friction entirely. Accounts that were difficult to pursue as a device OEM division are now simply accounts. When Dave Sheppard ran an OEM business group serving customers such as GE HealthCare, he frequently heard GE executives remark, “We’re often our own worst supplier” when referring to the company’s internal supply operations. Conversely, when Tyco Healthcare purchased his OEM business unit, it became difficult for Sheppard to visit a customer like Ethicon, as it was a fierce competitor to Tyco before the acquisition.

The third change is timing. A financial sponsor-backed platform operates on a defined hold period. Acquisitions, capacity investment, and share gain get front-loaded into the first two or three years, and nothing about those activities is leisurely. ROI has a clear timetable.

From product launches to M&A and manufacturing trends, the MPO Source delivers the medtech news you need twice a week. Subscribe here!

Overnight Changes to the Competitive Set 

For the mid-market medtech OEM supplier, this is the immediate impact. Companies competing in extrusion, catheter assembly, surgical fiber, precision machining, or micro molding are no longer competing against a division managed for cash contribution. Rather, they are competing against a focused independent with a growth mandate, a recapitalized balance sheet, and a board that measures management on share gain.

That shows up in ways customers notice: engineering and design-for-manufacturability support, program management depth, validated capacity, dual-site risk mitigation, and the ability to carry a program from concept through commercial launch. Thus, keep a close eye on INGENYX—it won’t be sitting still for long.

A New Potential Buyer Universe

Now for the good news: Every newly capitalized platform is also a bolt-on acquirer (looking for inorganic growth), and 2026 has produced a steady cadence of supplier-side transactions.

In deals noted by MPO, Resonetics moved twice in January, acquiring Resolution Medical and Med-Ally’s pulse generator manufacturing assets. Arterex acquired Irish CDMO Synecco, Symmetry Laser added ArcRev, MGS acquired Denmark’s Knudsen Plast A/S, and Plastic Ingenuity acquired German thermoformer Spezi-Pack. Cordica Medical bought RapidWerks micro molding capabilities, and Cretex Medical purchased select assets of Holland Molds Inc. At the larger end, Novanta Inc. agreed to acquire Riverpoint Medical from Arlington Capital for $1.2 billion upfront, Windjammer Capital acquired PrecisionX Group, and Axel Johnson Inc. acquired Fort Wayne Metals Research Products LLC.

That is not a handful of isolated deals. It is a pattern and a real dynamic in medtech. For a specialty supplier in the $10 million to $50 million revenue range, the most motivated buyer in 2027 may well be a company that has recently consolidated or it simply may be one that did not exist as an independent entity in 2025. 

Value = Strategic Fit + Timing

MedWorld Advisors’ guiding principle applies here as directly as it does at the MPO Top 30 level.

Strategic fit has high clarity at the moment. Newly independent platforms often publish their capability gaps in their own press releases. A medtech OEM supplier that fills a stated gap is worth materially more to that potential acquirer.

Timing matters just as much. Private equity appetite is front-loaded, and integration bandwidth is finite. The window during which a platform is actively hunting in a specific category is measured in quarters, not years.

Companies considering an exit window in 2027 should consider taking the following six actions this quarter:

• Re-mapping their competitive set, naming the newly independent platforms operating in their respective lane(s).
• Stress-testing customer concentration against each major customer’s declared portfolio direction.
• Rewriting their capability stories in an acquirer’s language: not what is made, but which gap can be closed.
• Getting on the radar of buyers before they fill gaps.
• Getting their financial houses in order so they can move inside 90 days if the right conversation begins.
• Engaging with a medtech-focused M&A advisor with a proven track record in this industry.

The Bottom Line

The MPO Top 30’s reshaping captures headlines because the numbers are enormous. But the second-order effect—the repricing and recapitalization of the supply base itself—is what will reorder the competitive landscape for many of the companies reading this magazine.

Two of medtech outsourcing’s most established names changed owners on the same Monday in August, and both will spend the next 24 months buying, hiring, investing, and taking share. Suppliers who read that as industry news will spend those months reacting. Suppliers who read it as a signal about their own positioning will spend that time choosing their own strategic priorities to maximize stakeholder value.

More from these authors—Shrink to Grow: What the Top 30’s Great Reshaping Means for Exits

Florence Joffroy-Black, CM&AA, and Dave Sheppard, CM&AA, are managing partners at MedWorld Advisors, a global M&A advisory firm serving the medical technology and life-science industries. Florence can be reached at [email protected]. Dave can be reached at [email protected].